AMSilk Achieves Large-scale Production Validation for Spidersilk® and Hires New CBO
|| Print ||
|Tuesday, 30 October 2012 08:00 (UTC + 1)|
Planegg, Germany, and Boston, USA, October 30, 2012 / B3C newswire / - AMSilk® achieved a large-scale production validation after a technical test campaign for the production of recombinant spider silk proteins (“Spidersilk®”). Spidersilk can now be manufactured at any available scale in the industry. This is a critical achievement in enabling the production of Spidersilk from the kilogram to the metric ton scale.
“We have clearly demonstrated that Spidersilk can be manufactured with a large-scale and economical, environmentally friendly process,” says Axel Leimer, CEO of AMSilk.
AMSilk develops processes in house and outsources manufacturing with a custom manufacturer for industrial-scale production.
“On this day we also welcome Mr. Mathias Woker to our team as our Chief Business Officer, says Axel Leimer. “Mr. Woker has extensive global experience in business development and licensing as well as product marketing in German and US-based enterprises. His role is important in translating our technology lead into business opportunities.”
Mr. Woker stated: “I am excited to join AMSilk at this important time in its growth and development toward a product- and market-driven enterprise.”
Mathias Woker has previously led the business development and licensing efforts of profitable biotech companies in Germany and the US and worked in a US-based strategic management consulting firm. Mr. Woker will be located in Boston, Massachusetts, and will head the US expansion of AMSilk.
AMSilk and Spidersilk are registered trademarks in the European Union and trademark applications in the USA of AMSilk GmbH, Germany.
Contact for the Americas: